Hello. I believe we have to expect more year-end selling from investors not wearing rose colored glasses. This selling is due to an almost obligatory year-end capital-loss selling as required by most shareholders and, an acute lack of buyers. Recall, share prices fell from the $10 level in March to recent $7.22 on eve of Qtr3 release, to the current "end-of-the-Company" $4.30 level.

Let us get through this next couple of weeks of ‘almost mandatory’ share selling and accept management’s stated intention is to continue monthly $841,000 distributions ($2.52M Qtr) and watch for the early-Christmas confirming press release coming our way very soon.

Importantly, Crius has not reported any new material change post Nov13. “Management believes that continued growth and diversification of revenues demonstrates our ability to support on-going distributions for investors.” Nov 13, pg 22, MD&A;

Also attending the Qtr3 conference call were analysts from RBC and BNS who asked management very insightful questions concerning increased cost centers and released their ‘hold’ reports Nov 15th. Crius’ shares price has looked down ever since. RBS downgraded the forward share price to $7.50 from $10 and BNS downgraded shares to $9 from $10. Combining analyst’s downgrades, year-end tax-selling via large annual share price losses is a potent mix to possible lower share price over the next 2-weeks.

Can we see near-term share price recoveries? Yes, maybe in December with any good news and in ’14 as management executes “show me” success with Qtr4 results required by the markets and analysts alike and by maintaining the $1 distributions. Zub

Hello. I believe we have to expect more year-end selling from investors not wearing rose colored glasses. This selling is due to an almost obligatory year-end capital-loss selling as required by most shareholders and, an acute lack of buyers. Recall, share prices fell from the $10 level in March to recent $7.22 on eve of Qtr3 release, to the current "end-of-the-Company" $4.30 level.

Let us get through this next couple of weeks of ‘almost mandatory’ share selling and accept management’s stated intention is to continue monthly $841,000 distributions ($2.52M Qtr) and watch for the early-Christmas confirming press release coming our way very soon.

Importantly, Crius has not reported any new material change post Nov13. “Management believes that continued growth and diversification of revenues demonstrates our ability to support on-going distributions for investors.” Nov 13, pg 22, MD&A;

Also attending the Qtr3 conference call were analysts from RBC and BNS who asked management very insightful questions concerning increased cost centers and released their ‘hold’ reports Nov 15th. Crius’ shares price has looked down ever since. RBS downgraded the forward share price to $7.50 from $10 and BNS downgraded shares to $9 from $10. Combining analyst’s downgrades, year-end tax-selling via large annual share price losses is a potent mix to possible lower share price over the next 2-weeks.

Can we see near-term share price recoveries? Yes, maybe in December with any good news and in ’14 as management executes “show me” success with Qtr4 results required by the markets and analysts alike and by maintaining the $1 distributions. Zub

Hello. I believe we have to expect more year-end selling from investors not wearing rose colored glasses. This selling is due to an almost obligatory year-end capital-loss selling as required by most shareholders and, an acute lack of buyers. Recall, share prices fell from the $10 level in March to recent $7.22 on eve of Qtr3 release, to the current "end-of-the-Company" $4.30 level.

Let us get through this next couple of weeks of ‘almost mandatory’ share selling and accept management’s stated intention is to continue monthly $841,000 distributions ($2.52M Qtr) and watch for the early-Christmas confirming press release coming our way very soon.

Importantly, Crius has not reported any new material change post Nov13. “Management believes that continued growth and diversification of revenues demonstrates our ability to support on-going distributions for investors.” Nov 13, pg 22, MD&A;

Also attending the Qtr3 conference call were analysts from RBC and BNS who asked management very insightful questions concerning increased cost centers and released their ‘hold’ reports Nov 15th. Crius’ shares price has looked down ever since. RBS downgraded the forward share price to $7.50 from $10 and BNS downgraded shares to $9 from $10. Combining analyst’s downgrades, year-end tax-selling via large annual share price losses is a potent mix to possible lower share price over the next 2-weeks.

Can we see near-term share price recoveries? Yes, maybe in December with any good news and in ’14 as management executes “show me” success with Qtr4 results required by the markets and analysts alike and by maintaining the $1 distributions. Zub